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Background: 2-Ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16) is a unique, in silico-designed compound
with possible anticancer properties, which were identified in our laboratory. This compound is capable of
interfering with microtubule dynamics and is believed to have potential carbonic anhydrase IX inhibiting activity.
In this study, it was investigated whether ESE-16 is capable of inducing apoptosis in vitro in the esophageal
carcinoma SNO cell line via the intrinsic pathway at a concentration of 0.2 μM with an exposure time of 24 hours.
Results: Qualitative results were obtained via light microscopy, transmission electron microscopy and confocal
microscopy. Results showed hallmarks of apoptosis in the ESE-16-treated cells. In addition, data revealed an increase
in the number of ESE-16-treated cells blocked in metaphase. Cell death via apoptosis in the ESE-16-treated cells was
confirmed by studying the internal ultrastructure of the cells via transmission electron microscopy, while confocal
microscopy revealed abnormal spindle formation and condensed chromatin in ESE-16-treated cells, thus confirming
metaphase block.
Quantitative results were obtained via flow cytometry and spectrophotometry. Cell death via apoptosis in ESE-16-treated
cells was quantitatively confirmed by the Annexin V-FITC apoptosis detection assay. Flow cytometry and
spectrophotometry revealed dissipation of mitochondrial membrane potential and an increase in superoxide
levels in the ESE-16-treated cells when compared to the relevant controls. Both initiator caspase 9 and effector
caspase 3 activities were increased, which demonstrates that ESE-16 causes cell death in a caspase-dependent manner.
Conclusions: This was the first in vitro study conducted to investigate the action mechanism of ESE-16 on an
esophageal carcinoma cell line. The results provided valuable information on the action mechanism of this
potential anticancer agent. It can be concluded that the novel in silico-designed compound exerts an anti-proliferative
effect on the esophageal carcinoma SNO cell line by disrupting microtubule function resulting in metaphase block.
This culminates in apoptotic cell death via the intrinsic apoptotic pathway. This research provided cellular targets
warranting in vivo assessment of ESE-16’s potential as an anticancer agent.
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Microtubule-interfering drugs (MIDs) are one of the most
promising classes of cancer chemotherapeutic drugs avail-
able [1-3]. MIDs target the cell cycle by binding to and
interfering with the microtubule machinery, thereby inhi-
biting the normal function of the mitotic spindle and pre-
venting hyperproliferation of cancer cells [1,4-6]. Owing* Correspondence: annie.joubert@up.ac.za
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article, unless otherwise stated.to the therapeutic success of MIDs, intense search and de-
velopment for new microtubule-targeting compounds are
being conducted by pharmaceutical companies [2].
2-Methoxyestradiol (2ME) (Figure 1A) is an endogenous
metabolite derived from 17β-estradiol [6-12] with antipro-
liferative, anti-angiogenic and pro-apoptotic characteristics
in vitro and in vivo [6-8,13,14] independent of estrogen re-
ceptors [6,12,15,16]. 2ME’s major target is the microtubule
skeleton [6,7,11,12,14,16]. The compound influences
the spindle assembly checkpoint (SAC) by interacting with
the colchicine binding site situated between the α- andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Structural comparison between (A) 2ME and (B) ESE-16. When the two chemical structures are compared, an exchange of a
sulphamoylated group for a hydroxyl group at position 3 and the removal of a hydroxyl group at position 17 on the ESE-16 compound are
noticed. The sulphamoylated group increases the bioavailability of the compound [8,13,20,28,29], while the modifications at position 3 and −17
increases the anticancer potency and provides a prolonged half-life [6,11,13,22,27,28].
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action causes abnormal spindle formation and activation
of the spindle checkpoint, which leads to metaphase ar-
rest, inhibition of further cell proliferation and the induc-
tion of cell death [6,10,11,19].
2ME, however, has been found to have low bioavail-
ability in the human body as a result of rapid metabolic
degradation by the enzyme 17β-hydroxysteroid dehydro-
genase type 2 in the gastrointestinal tract and liver
[8,13,20-22]. The compound is registered as “Panzem”
by Entremed Inc. (Rockville, Maryland, USA) and is cur-
rently undergoing clinical trials with an innovative nano-
crystal dispersion (NCD) drug delivery system which
may possibly overcome the rapid biodegradation prob-
lem [23-26].
Researchers have attempted to create analogues of 2ME
with improved bioavailability and potency. The analogue
being investigated in this research was the latest in silico-
designed 2ME derivative: 2-ethyl-3-O-sulphamoyl-estra-
1,3,5(10)16-tetraene (ESE-16). ESE-16 (Figure 1B) was
developed when potential carbonic anhydrase IX (CAIX)
inhibitors, capable of interfering with microtubule dynamics
were identified in our laboratory with the use of bioinfor-
matics software [8].
When the chemical structures of ESE-16 and 2ME are
compared (Figure 1), an exchange of a sulphamoylated
group for a hydroxyl group at position 3 and the re-
moval of a hydroxyl group at position 17 on the ESE-16
compound are noticed. Previous studies have shown sul-
phamoylated analogues with modifications on the 3- and
17-position of the molecule revealed significant antican-
cer potency and prolonged half-life and bioavailability
[6,11,13,22,27,28]. Increased bioavailabilty is due to the
ability of the sulfamoylated derivatives to reversibly bind
to carbonic anhydrase II (CAII) found in red blood cells,
thereby enabling them to journey through the liver with-
out undergoing presystemic metabolism [8,13,20,28,29].Our laboratory has demonstrated the anti-proliferative
action of ESE-16 in a variety of cell lines: the tumori-
genic human epithelial cervical HeLa cell line, MCF-7
breast cancer cell line, esophageal carcinoma SNO cell
line, metastatic MDA-MB-231 breast cancer cell line
and the non-tumorigenic MCF-12A cell line [8,29-32].
Studies have also revealed ESE-16 to be more potent
than its source compound, 2ME [8]. Research has shown
that 2ME exerts antiproliferative effects at concentra-
tions between 1-2 μM, whereas ESE-16 has shown anti-
proliferative activity at nanomolar values, with a GI50
value of 180-220nM [8].
The exact action mechanism of ESE-16, however, still
remains to be elucidated. This in vitro study was the first
to investigate the action mechanism of ESE-16 on an
esophageal carcinoma cell line.
It was hypothesized that ESE-16 uses the intrinsic
apoptotic pathway as an action mechanism to cause cell
death. In the hypothesized chain of events the com-
pound binds to the microtubules of the esophageal
carcinoma cells, causing the activation of the SAC and
subsequent metaphase arrest. This leads to increased
reactive oxygen species (ROS) production, mitochon-
drial membrane potential (ΔΨm) dissipation, degrad-
ation of the mitochondrial membrane and the release of
cytochrome c. Cytochrome c then binds with apoptotic
protease activating factor 1 (Apaf-1) to form the apop-
tosome, which activates the initiator caspase 9. Caspase
9 activates the effector caspase 3, which then leads to
the cell undergoing apoptosis.
The results provided valuable information on the action
mechanism of this potential anticancer agent. It can be
concluded that the novel in silico-designed compound ex-
erts an anti-proliferative effect on the esophageal carcin-
oma SNO cell line by disrupting microtubule function,
resulting in metaphase block. This culminates in apoptotic
cell death via the intrinsic apoptotic pathway.
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Haematoxylin and eosin staining show morphological
changes in the ESE-16-treated SNO cells
Haematoxylin and eosin (H&E) staining allows for the
quantitative comparison of the morphological character-
istics of the cytoplasm and nuclear components of the
cells [10]. The staining was used to visualize morpho-
logical changes in SNO cells after exposure to ESE-16
and the appropriate controls. Cells propogated in
medium (Figure 2A) and the vehicle control (Figure 2B)
showed normal cell morphology with the majority of the
cells being in interphase. The positive control for apop-
tosis (Figure 2C) and ESE-16-treated cells (Figure 2D)
showed a decrease in cell density and morphological
characteristics of apoptosis such as membrane blebbingFigure 2 Haematoxylin and eosin staining images revealing morphol
SNO cells. (A) Cells propogated in medium only, (B) cells exposed to dime
actinomycin D – positive control and (D) cells exposed to ESE-16 at a concen
cells showed normal cell morphology, with the majority of the cells being
treated cells showed a decrease in cell density and morphological charac
bodies. The ESE-16 treated cells also showed an increase in the number o
block (Magnification: ×20).and apoptotic bodies. ESE-16-treated cells also showed
an increase in the number of round cells with hypercon-
densed chromatin indicative of metaphase block.
In order to obtain quantitative data from this morpho-
logical study, mitotic indices were determined (Table 1)
[10]. One thousand cells were counted on each slide of
the biological replicates and divided into their different
phases [10,33]. Identification of cells in interphase, the
different mitotic phases and cells undergoing apoptosis
were done based on their cellular and nuclear morph-
ology [34]. Cells that could not be categorized as a result
of excessive fragmentation, unusual nuclear morphology
or a lack of clear nuclear material were defined and
counted as abnormal [11]. The data is expressed as per-
centages of cells in each phase. Mitotic indices revealedogical changes in the nuclear and cytoplasmic components in
thyl sulphoxide (DMSO) – vehicle control, (C) cells exposed to
tration of 0.2 μM. Cells propogated in medium and the vehicle-treated
in interphase. The positive control for apoptosis and the ESE-16
teristics of apoptosis such as membrane blebbing and apoptotic
f round cells with hypercondensed chromatin indicative of a metaphase
Table 1 Average percentage of cells in interphase, various stages of mitosis and cells displaying apoptotic morphology
Interphase Prophase Metaphase Anaphase Telophase Apoptosis Abnormal
Medium 96.1% 0.6% 1.5% 0.4% 0.6% 0.5% 0.4%
DMSO 97.5% 0.2% 1.3% 0.2% 0.6% 0.2% 0.4%
Actinomycin D 60.2% 0.3% 2.5% 0% 0.5% 33.8% 2.3%
ESE-16 27.3% 0.7% 46.0%* 0.2% 0.4% 21.4%* 4.2%
Mitotic indices revealed a significant increase, with a P-value of 0.0003*, in the percentage of cells in metaphase in the ESE-16-treated samples (46.0%) when
compared to the vehicle control (1.3%). ESE-16-treated cells also showed a significant increase (P-value of 0.0006*) in the percentage of cells undergoing
apoptosis (21.4%) when compared to the vehicle control (0.2%).
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percentage of cells in metaphase in the ESE-16-treated
samples when compared to controls. ESE-16-treated
cells also showed a significant increase in the percentage
of cells undergoing apoptosis when compared to the ap-
propriate controls (P-value of 0.0006)*.Figure 3 Transmission electron microscopy images providing informa
medium only and SNO cells treated with DMSO. (A) Cells propogated i
exposed to actinomycin D – positive control and (D) cells exposed to ESE-
and the vehicle control cells showed microvilli protruding from their cell m
well-preserved cytoplasmic organelles are visible. The positive control for a
presence of apoptotic bodies. ESE-16-treated cells revealed a decrease in n
formation. Scale bar: 5 μm.Transmission electron microscopy shows changes in the
internal ultrastructure of the ESE-16-treated SNO cells
Transmission electron microscopy (TEM) was used to
study the internal ultrastructure of the SNO cells after
exposure to ESE-16 and the appropriate controls. Results
revealed normal infrastructure of cells propogated intion on the internal ultrastructure of SNO cells propogated in
n medium only, (B) cells exposed to DMSO – vehicle control, (C) cells
16 at a concentration of 0.2 μM. Both the cells propogated in medium
embrane surface. The nuclear membrane is smoothly outlined and
poptosis showed loss of microvilli, membrane blebbing and the
uclear membrane definition, membrane blebbling and apoptotic body
Wolmarans et al. Cell & Bioscience 2014, 4:68 Page 5 of 14
http://www.cellandbioscience.com/content/4/1/68medium (Figure 3A) and in the vehicle control
(Figure 3B). Both the cells propogated in medium and
the vehicle control revealed microvilli protruding from
their cell membrane surface, a smoothly outlined nu-
clear membrane and well-preserved cytoplasmic organ-
elles. The positive control for apoptosis (Figure 3C)
showed loss of microvilli, membrane blebbing and the
presence of apoptotic bodies. An ESE-16-treated cell
image (Figure 3D) revealed a decrease in nuclear mem-
brane definition, membrane blebbling and apoptotic
body formation.
Confocal microscopy reveals the effect ESE-16 has on the
microtubule architecture of the SNO cells
Confocal microscopy was used to determine the influence
of ESE-16 on the cytoskeletal microtubule architecture ofFigure 4 Confocal microscopy images of the microtubule architecture
nuclear stain 4′,6-diamidino-2-phenylindole. (A) Cells propogated in me
exposed to actinomycin D – positive control and (D) cells exposed to ESE-
green by a FITC-conjugate diluent while the nuclei were stained blue by D
medium and vehicle control cells showed normal microtubule architecture
shrunken cells. ESE-16-treated cells showed a decrease in cell density and a
controls. The abnormal spindle formation is indicative of metaphase block.SNO cells after exposure to ESE-16 and the appropriate
controls. Cells were stained with mouse monoclonal anti-
body against human α-tubulin and a secondary antibody,
biotin-conjugated anti-mouse IgG 58 (Fab-specific, devel-
oped in goat) in a fluorescein isothiocyanate (FITC)-conju-
gate diluent, which stained the α-tubulin of the cells
green. 4′,6-Diamidino-2-phenylindole (DAPI) was used to
stain the nuclei of the cells blue to provide contrast to the
green stain. Cells propogated in medium (Figure 4A)
and vehicle control cells (Figure 4B) showed normal
microtubule architecture. The positive control
(Figure 4C) showed a decrease in cell density and re-
vealed shrunken cells. The ESE-16-treated cells
(Figure 4D) also showed a decrease in cell density and
revealed abnormal spindle formation, indicating cells
being blocked in metaphase.of SNO cells with the use of anti-α tubulin antibodies and
dium only, (B) cells exposed to DMSO – vehicle control, (C) cells
16 at a concentration of 0.2 μM. The α-tubulin of the cells were stained
API to provide contrast to the green fluorescence. Cells propogated in
. The positive control showed a decrease in cell density and revealed
bnormal spindle formation when compared to the appropriate
Scale bar: 10 μm.
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Annexin V-FITC, a well-known apoptosis-detecting assay,
was used to confirm that apoptosis was taking place in the
SNO cells after exposure to ESE-16 (Figure 5). Results re-
vealed an average increase in the mean fluorescent inten-
sity (MFI) in the ESE-16-treated cells (average of 25.50)
when compared to the vehicle control with an average
MFI of 11.32. The increase in MFI indicates an increase in
phosphatidylserine (PS) externalization, which is an early
apoptotic indicator [35]. The P-value obtained for this ex-
periment, however, was 0.0614, which is statistically insig-
nificant. The statistically insignificant increase may be due
to the fact that PS externalization is an early sign of apop-
tosis and that, at the time of experiment termination, the
cells may have already surpassed the early apoptotic stage.
This may also explain the low MFI value of the positive
control (average of 18.82).
Decrease in mitochondrial membrane potential in
ESE-16-treated SNO cells
The Mitotracker Kit was used to study the possible
influence ESE-16 has on the ΔΨm of the SNO cells.
The mitochondria are labeled by a cationic dye named
“5,5′,6,6’-tetrachloro-1,133’-tetra-ethylbenzimidazolyl-
carbocyanine iodide”, which passively diffuses across the
plasma membrane and accumulates in active mitochondria
[36]. Reduction of the ΔΨm is another feature of apoptosis
that is due to the loss of the electrochemical gradient across
the mitochondrial membrane. With the reduction of the
ΔΨm, the mitotracker dye cannot aggregate in the mito-
chondria and thus remains in the cytoplasm in its mono-
mer form, generating green fluorescence [36].Figure 5 Bar graph showing the average mean fluorescent
intensity increase in the ESE-16-treated cells compared to the
appropriate controls illustrating an increase in
phosphatidylserine externalization. This bar graph represents the
average MFI of all three repeats done. Cells propogated in medium
had an average MFI of 11.31, the vehicle control had an average MFI
of 15.74, the positive control had an average MFI of 18.82 while the
ESE-16-treated cells an average MFI of 25.50. The increased MFI indi-
cates an increase in PS externalization which is an early apoptotic
indicator [35].Results obtained showed a statistcally significant (P-value
of 0.019)* increase in the MFI of green fluorescence in the
ESE-16-treated cells when compared to the appropriate
controls (Figure 6). These results demonstrate the ability
of ESE-16 to cause a decrease in ΔΨm. These findings
confirm the qualitative and quantitative data obtained with
regard to ESE-16 causing apoptosis at a concentration of
0.2 μM after an exposure time of 24 hours. The results
also provide evidence of the degradation of the mitochon-
drial membrane, indicating apoptotic cell death via the
intrinsic pathway.
Increase in superoxide levels in ESE-16-treated SNO cells
The accumulation of ROS may lead to oxidative damage
to mitochondrial proteins and mitochondrial deoxyribo-
nucleic acid (DNA), causing loss of electron transport,
decrease in adenosine triphosphate (ATP) production
and ΔΨm dissipation [37-40]. Superoxide anion (O2
−)
can be regarded as the precursor for most ROS [40].
Thus, flow cytometry was used to measure O2
− levels in
the SNO cells after exposure to ESE-16 and the various
controls (Figure 7).
Viable cells represent the population of cells that
showed little or no increase in fluorescence, thus no in-
crease in O2
− production. Non-viable cells represent the
population of cells with an increase in fluorescence, thus
indicating an increase in O2
− production. Results re-
vealed an increase in O2
− production in the ESE-16
treated cells with 38.17% of its population being non-
viable when compared to the 21.45% non-viable popula-
tion of the vehicle control (Table 2). Results indicate thatFigure 6 Bar graph showing the average mean fluorescent
intensity increase in the ESE-16-treated cells compared to the
appropriate controls, illustrating a decrease in mitochondrial
membrane potential. This bar graph represents the average MFI of
all three repeats done. The vehicle control had an average MFI of
28.79 while the postive control had an average MFI of 45.58 and the
ESE-16-treated cells an average MFI of 37.995. The increase in the
MFI seen in the ESE-16-treated cells is statistically significantly
(P-value of 0.019)* higher than that of the vehicle control indicating
a decrease in ΔΨm and possible mitochondrial membrane
degradation.
Figure 7 Histograms illustrating superoxide levels in SNO cells after exposure to ESE-16 and the appropriate controls of a representative
repeat. (A) Cells propogated in medium only, (B) cells exposed to DMSO – vehicle control, (C) cells exposed to actinomycin D – positive control
and (D) cells exposed to ESE-16 at a concentration of 0.2 μM. Viable cells represent the population of cells which showed little or no increase in
fluorescence, thus no increase. The non-viable cells represent the population of cells with an increase in fluorescence thus indicating an increase in
O2
− production. The ESE-16-treated cells showed 38.17% of its population to be non-viable compared to the 21.45% non-viable population
of the vehicle control.
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− levels, which may
lead to mitochondrial degradation and cell death. This
confirms results obtained from studying the ΔΨm.
Increase in caspase activity in the ESE-16-treated SNO cells
The activity of initiator caspase 9 and the effector caspase
3 in SNO cells after exposure to ESE-16 or the appropriate
controls was studied via spectrophotometry. Results,
showing the average ratio to medium, revealed an increase
in both caspase 9 and caspase 3 activity in the ESE-16-
treated cells when compared to the vehicle control.
The initiator caspase 9 results (Figure 8) showed that
ESE-16-treated cells had a ratio to medium value of
1.2188, while the vehicle control had a value of 1.0625.Table 2 Percentages of viable and non-viable cells of the
representative repeat, illustrating superoxide levels in
SNO cells after exposure to ESE-16 and the appropriate
controls
Medium DMSO Actinomycin D ESE-16
Viable cells 75.18% 77.90% 22.61% 60.11%
Non-viable cells 23.45% 21.05% 75.29% 38.17%This is not a statistically significant increase (P-value of
0.238) when compared to the difference in caspase 3 ra-
tio to medium values. The effector caspase 3 results
(Figure 9) showed ESE-16-treated cells had an average
ratio to medium value of 2.9772 while the vehicle con-
trol had a value of 1.0681. This is a statistically signifi-
cant increase, with a P-value of 0.004*.
The difference in the increase of activity of the two
caspases may be explained by the fact that the effector
caspase 3 had already, at the time of measurement,
begun the degradation phase of apoptosis [35,41], caus-
ing a decrease in caspase 9 levels. The caspase activity
results show that ESE-16 causes the activation of cas-
pases and reveals that ESE-16 causes cell death in a
caspase-dependent manner.
Discussion
ESE-16, a unique, in silico-designed compound was de-
signed with the dual capability of interfering with micro-
tubule dynamics [1] and inhibiting CAIX, which is over-
expressed in a variety of tumours [8,42]. These two tar-
gets were chosen because: 1) several studies have shown
that inhibition of CAIX can lead to decreased
Figure 8 Bar graph illustrating the ratio to medium of the
initiator caspase 9 levels in SNO cells exposed to ESE-16 and
various controls. Results revealed a statistically insignificant increase
(P-value of 0.238) in caspase 9 activity in the ESE-16-treated cells
when compared to the vehicle control. The ESE-16-treated cells had
a ratio to medium value of 1.2188, while the vehicle control had a
ratio to medium value of 1.0625.
Figure 9 Bar graph illustrating the ratio to medium of the
effector caspase 3 levels in SNO cells exposed to ESE-16 and
various controls. Results revealed a statistically significant increase
(P-value of 0.004)* in caspase 3 activity in the ESE-16-treated cells
when compared to the vehicle control. The ESE-16-treated cells had
a ratio to medium value of 2.9772, while the vehicle control had a
ratio to medium value of 1.0681.
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conditions [42] and 2) by binding to microtubules there
is interference during cell division, which may lead to
cell death [1,4-6].
In this study ESE-16 was shown to induce apoptosis
in vitro in the esophageal carcinoma SNO cell line via
the intrinsic pathway at a concentration of 0.2 μM with
an exposure time of 24 hours. The concentration of
0.2 μM for ESE-16 was chosen since previous dose-
dependent investigations conducted in our laboratory
showed ESE-16 inhibiting cell proliferation to 50% from
concentrations ranging from 0.18 μM to 0.22 μM [8].
Qualitative results were obtained via H&E staining,
TEM and confocal microscopy and provided informa-
tion on morphological changes, microtubule architecture
and internal ultrastructures of the SNO cells after expos-
ure to ESE-16. The H&E results revealed the presence
of apoptotic morphological characteristics, such as
membrane blebbing and apoptotic bodies in the ESE-
16-treated. These results were confirmed by studying
the internal ultrastructure of the cells via TEM. Results
revealed lack of definition of the nuclear membrane,
membrane blebbling and apoptotic body formation in
the ESE-16-treated cells when compared to the appro-
priate controls.
Apoptosis occuring in ESE-16-treated SNO cells were
studied quantitatively via mitotic indices and the Annexin
V-FITC apoptosis-detection assay. Mitotic indices quanti-
fied the observed effects in the H&E staining images and
revealed a statistically significant increase (P-value of
0.0006)* in the percentage of ESE-16-treated cells undergo-
ing apoptosis when compared to the appropriate controls.
Results from the Annexin V-FITC apoptosis-detection
assay revealed a statistically insignificant increase in MFI
(P-value of 0.0614) of the ESE-16-treated cells whencompared to the appropriate controls. The increased MFI
indicates an increase in PS externalization, which is an early
apoptotic indicator [35]. The insignificant increase in MFI
may be ascribed to the fact that at the time of experimental
termination, the cells may have already surpassed the early
apoptotic stage. When combined with the qualitative and
quantitative results obtained via mitotic indices, H&E stain-
ing and TEM, a relationship between ESE-16 exposure and
apoptosis can be observed. In addition, the authors have
previously demonstrated that the ESE-16 compound in-
duces apoptosis in the esophageal carcinoma cell line
with propidium iodide inclusion [32]. In the article by
Wolmarans et al. cell cycle analysis was performed to study
the influence of ESE-16 on the cell cycle progression of the
SNO cell line. An increase in the percentage of cells in the
sub G1 (indicative of apoptosis) in the ESE-16-treated cells
was observed when compared to the relevant controls [32].
These results correlates with the findings of Nkandeu
et al., who tested ESE-16 on MCF-7 breast carcinoma
cell line [31]; Theron et al., who tested ESE-16 on the
tumorigenic human epithelial cervical HeLa cell line
[30] and Stander et al. who tested ESE-16 on the
tumorigenic MCF-7, the metastatic MDA-MB-231 and
the non-tumorigenic MCF-12A breast cancer cells [29].
In a comparison of ESE-16 and 2ME’s ability to induce
cell death, similarities exist. The effects of 2ME have
been studied on various cell lines, including the MCF-7
cell line, the estrogen receptor-negative breast carcinoma
cell line MDA-MB-435, the human ovarian adenocarcin-
oma cell line OVCAR-3 and the renal carcinoma cell
line SN12-C [43]. Du et al. studied the effects of 2ME
on the esophageal carcinoma EC9706 cell line in a time-
and dose-dependent study and showed an increase in
apoptosis in the 2ME-treated cells after 24 hours at con-
centrations of 5 μM and 10 μM [7]. Cell death via apop-
tosis and due to 2ME exposure was also found by
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tested the effects of 1 μM 2ME on the MCF-7 breast
cancer cell line and the esophageal carcinoma WHCO3
cell line respectively [44,45]. In comparing results ob-
tained after 24 hours by 1 μM, 5 μM and 10 μM 2ME
and 0.2 μM ESE-16 used in this study, the increased po-
tency of ESE-16 can be observed.
ESE-16 has a similar mechanism to that of 2ME, its
source compound, and thus also binds to the colchicine
binding site situated between the α - and β-dimers of
the tubulin protein [8,9,14,17,18]. It was hypothesized
that ESE-16 would, like its source compound, cause ab-
normal spindle formation and activate the SAC, causing
metaphase arrest. This would lead to the inhibition of
cell proliferation and cell death. Qualitative and quanti-
tative data obtained in this study indicate that ESE-16
blocks the cells in metaphase.
H&E images revealed hypercondensed chromatin in
the ESE-16-treated cells when compared to the appro-
priate controls. Mitotic indices revealed a significant
increase, with a P-value of 0.0003*, in the percentage of
cells in metaphase in the ESE-16-treated samples when
compared to the controls. The observed effect of ESE-16
on the microtubules was qualitatively confirmed via con-
focal microscopy, which also showed hypercondensed
chromatin and abnormal spindle formation in the ESE-16-
treated cells when compared to the appropriate controls.
2ME has been shown to cause metaphase block in a
variety of cell lines (including the MCF-7 cell line, the
EC9706 cell line, the WHCO3 cell line and the MDA-
MB-435 breast cancer cell line) at concentrations of
1 μM, 2 μM, 5 μM and 10 μM after 24 hours of expos-
ure [7,19,44,45]. The increased potency of ESE-16 can
once again be seen, since it was able to cause metaphase
block in the SNO cell line after 24 hours’ exposure at a
much lower concentration of 0.2 μM.
The mitochondria’s role in the regulation of cell death
is well established [40] and is considered to be the cen-
tral death machinery in the intrinsic apoptotic pathway
[35,46-48], with the key step believed to be mitochon-
drial membrane permeabilization (MMP) [2,41,46-48].
The possible effect that ESE-16 had on the mitochon-
dria of the SNO cells after exposure was studied by
means of flow cytometry by quantitatively analyzing
ΔΨm and ROS production in the SNO cells after ESE-
16 exposure.
Results obtained from studying the ΔΨm showed a
statistcally significant (P-value of 0.019)* increase in the
MFI in the ESE-16-treated cells when compared to the
vehicle control. These findings illustrate that ESE-16
caused a decrease in ΔΨm, which may have led to the
degradation of the mitochondrial membrane and apop-
tosis. Since MMP of the mitochondria is considered a
key step in the intrinsic apoptotic pathway [2,41,46-48],these results provide evidence of apoptosis taking place
via the hypothesized pathway.
The decrease of ΔΨm due to ESE-16 exposure was also
found by Stander et al. in the tumorigenic MCF-7 and
MDA-MB-231 cell lines. In addition, Stander et al.
showed that ESE-16 had a more pronounced effect on the
tumorigenic cell lines when compared to the non-
tumorigenic MCF-12 cell line [29]. The difference in ef-
fects shows possible selectivity of ESE-16 toward the more
malignant cell lines when compared to non-malignant
cell lines.
The mitochondria are both the major source of intra-
cellular ROS and, at the same time, targets of ROS
[38,39,48]. ROS are natural by-products from the pro-
duction of ATP, which occurs in the mitochondrial
matrix via the oxidative phosphorylation pathway
[38,40,49,50]. The accumulation of ROS may lead to oxi-
dative damage to mitochondrial proteins and DNA,
causing loss of electron transport, decrease in ATP pro-
duction and ΔΨm dissipation [39,40].
Since O2
− can be regarded as the precursor for most
ROS [40], the levels of O2
− were measured via flow
cytometry in the SNO cells after ESE-16 exposure.
Results revealed an increase in O2
− levels in the ESE-
16-treated cells when compared to the relevant con-
trols. This increase shows that ESE-16 causes oxidative
stress after 24 hours’ exposure and confirms previously
discussed results of ΔΨm dissipitation, since it is be-
lieved that ROS can cause ΔΨm dissipation [39,40]. In
addition, ROS accumulation is also believed to act as
signaling molecules, which may initiate MMP via the
permeability transition pore (PTP), causing the release
of the pro-apoptotic proteins found in the intermem-
brane space [39,51].
Several studies have linked 2ME with the increase in
ROS production, specifically O2
− [6,37]. Chua et al.
showed, however, that 2ME induced only a moderate in-
crease in cellular superoxide while analogues of 2ME ex-
tended stronger ROS production, thus suggesting that
ROS induction is not a major mechanism of action for
2ME [6]. This correlates with the Stander et al. paper of
2010, which showed that 2ME-treated MCF-7 cells had
no significant increase in O2
− levels compared to the ve-
hicle control [44]. By studying various analogues of
2ME, Chua et al. suggest that the 2-methoxy group at
position 2 in the 2ME compound structure is not re-
quired for ROS production and may even have an inhibi-
tory effect [6]. In addition, Chua et al. show an increase
in O2
− levels due to 2ME analogues that had modifica-
tions done on positions 3 and 17 [6]. The increased O2
−
production due to ESE-16 might be due to the conform-
ational changes in the ESE-16 compound structure.
After the key step in the intrinsic pathway, believed to
be MMP [2,41,46-48], several pro-apoptotic proteins,
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cytosol [46-48,52-54]. Once released, cytochrome c binds
to Apaf-1, allowing deoxyadenosine triphosphate (dATP)
to bind onto Apaf-1; inducing conformational changes
and causes the oligomerization of Apaf-1 into the Apaf-
1 apoptosome [35,46-48,53,54]. This apoptosome subse-
quently recruits and activates the initiator procasapase
9, which in turn activates downstream effector caspases
such as caspase 3, leading to the execution phase of
apoptosis [35,46-48,53,54].
Caspase activity in the SNO cells after exposure to
ESE-16 was quantitatively studied via spectrophotom-
etry. Results revealed a statistically insignificant (P-value
of 0.238) increase in caspase 9 activity in ESE-16-treated
cells when compared to the relevant controls. In com-
parison, caspase 3 results showed a statistically signifi-
cant increase in activity with a P-value of 0.004* in the
ESE-16-treated cells when compared to the appropriate
controls. The difference in the increase of activity of
the two caspases might be explained by the fact that
the effector caspase 3 had already, at the time of meas-
urement, begun the degradation phase of apoptosis
[35,41] and caused a decrease in caspase 9 levels. The
caspase activity results show that ESE-16 causes the ac-
tivation of caspases and induces cell death in a caspase-
dependent manner.
Conclusion
This was the first study conducted to investigate the ac-
tion mechanism of the ESE-16 compound on an esopha-
geal carcinoma cell line. In addition to obtaining
information of the action mechanism of ESE-16, this
study confirmed the increased potency of this compound
compared to its source compound, 2ME.
From this study, it can be concluded that the novel in
silico-designed compound induces cell death at a con-
centration of 0.2 μM, with an exposure time of 24 hours,
in the esophageal carcinoma SNO cell line by disrupting
microtubule function. This study unraveled the action
mechanism of this novel compound and provides cellu-
lar targets for future in vivo studies to establish the
counpound’s efficacy as a clinically usable anticancer
agent. Future studies will investigate the action mechan-
ism of this compound on areas such as angiogenesis;
will test whether it exerts any significant side effects
and test whether the in silico-design has increased the
compounds’ bioavailability.
Materials and methods
Esophageal carcinoma cell line
SNO esophageal carcinoma cells are non-keratinizing
squamous epithelial cells [55] and were purchased from
Highveld Biological (Pty) Ltd (Sandringham, SA). The
cell line was derived from a well-differentiated squamouscell carcinoma, 6.5 cm in length and metastatic to the
lymph nodes, from a Zulu male aged 62 in 1976 [55].
In silico-designed compound
The unique, non-commercially available ESE-16 compound
was in silico-designed with the use of the Chimera package
from the Resource for Biocomputing, Visualization and
Informatics at the University of California, San Francisco
(supported by NIH P41 RR-01081), which was used for
structure preparation and visualization of the compound
[8]. Docking studies were carried out with Autodock 4.0
and AutoDockTools4 (Scripps Research Institute, La Jolla,
CA, USA) [8]. The ESE-16 compound was synthesized
by iThemba Pharmaceuticals (Pty) Ltd (Modderfontein,
Gauteng, SA).
General laboratory reagents and supplies
Dulbecco’s Modified Eagle Medium (DMEM) and F-12
Nutrient Mixture, formulated from single-cell plating
of Chinese Hamster Ovary (CHO) cells (HAM’s-F12),
was obtained from Sigma-Aldrich Co. (St. Louis, USA).
Penicillin, streptomycin, fungizone, gentamycin and tryp-
sin were obtained from Highveld Biological (Pty) Ltd
(Sandringham, SA). Phosphate-buffered saline (PBS) was
purchased from Gibco-BRL (Invitrogen, Carlsbad, CA,
USA). Dimethyl sulphoxide (DMSO), trypan blue, RNase
A, Bouin’s fixative and actinomycin D was purchased
from Sigma-Aldrich Co. (St Louis, USA). Ethanol was
purchased from Merck (Darmstadt, Germany). Fetal
calf serum (FCS), sterile cell culture flasks, cell culture
plates and syringe filters (0.22 μM) were obtained from
Separation Scientific (Randburg, SA). Haematoxylin, eosin,
ethanol and xylol were purchased from Merck (Darmstadt,
Germany). Alpha-tubulin antibody, alexafluor 488, DAPI
and the Mitotracker kit was purchased from Biocom
Biotech Pty Ltd. (Clubview, SA). The Annexin V-FITC
Apoptosis Detection Kit and the Caspase 3 and - 9 Colori-
metric Kits were purchased from BioVision (Mountain
View, California, USA).
Experimental procedures
Experiments were conducted at a concentration of
0.2 μM with a 24-hour seeding time to allow for attach-
ment and a 24-hour exposure time in a humidified at-
mosphere (37°C with 5% CO2). A stock solution of
10 mM ESE-16 was dissolved in DMSO and diluted with
medium to the desired concentration prior to exposure
of the cells. The concentration of 0.2 μM for ESE-16 was
chosen, since previous dose-dependent investigations
conducted in our laboratory showed ESE-16 inhibiting
cell proliferation to 50% from concentrations ranging
from 0.18 μM to 0.22 μM [8].
Experiments were conducted in 6-well plates or
25 cm2 cell culture flasks. For 6-well plates, cells were
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105 cells per well in 3 ml of medium. For 25 cm2 cell
culture flasks, cells were seeded at 1 × 106 cells in 5 ml
of medium.
Appropriate controls were included: cells propagated
in complete medium only, a vehicle control that was
composed of cells treated with DMSO, the final dilution
never exceeding 0.02% (v/v) [15,56]. Actinomycin D
(0.1 μg/ml in growth medium) was used as a positive
control for the induction of apoptosis [56].
Light microscopy
Haematoxylin and eosin staining
H&E staining allows for the quantitative comparison of
the morphological characteristics of the cytoplasm and
nuclear components [10]. Hematoxylin has a deep blue-
purple color and stains nucleic acids while eosin is pink
and stains proteins nonspecifically [57]. Thus, during
a general H&E staining experiment, the nuclei of the
cells are stained blue, whereas the cytoplasm and extra-
cellular matrix are stained varying degrees of pink [57].
In order to obtain quantitative data from the morpho-
logical study, mitotic indices were determined as de-
scribed above [10].
SNO cells were seeded in complete growth medium at
5 × 105 cells per well in 6-well plates on heat-sterilized
coverslips. Cells were exposed to ESE-16 and the appro-
priate controls. After the 24-hour incubation period,
coverslips were removed from the wells and transferred
to a staining dish. Bouin’s fixative was added to the
staining dish until the entire sample slide was covered.
Samples were incubated at room temperature for 30 min
after which the Bouin’s fixative was replaced with 70%
ethanol for 20 min to dehydrate the cells. Excess fixative
was removed and the staining dish was rinsed with
tap water to remove excess ethanol. Haematoxylin
was added and the samples were incubated at room
temperature for 20 min. The staining dish was rinsed
with tap water for 2 min and then rinsed with 70% etha-
nol to remove any excess stain. Eosin (1%) was added to
the staining dish and samples were incubated at room
temperature for 2 min. The staining dish was rinsed
twice for 5 min with 70% ethanol, twice for 5 min with
96% ethanol, twice for 5 min with 100% ethanol and
twice for 5 min with xylol. Coverslips were mounted on
microscope slides with resin and left overnight to dry.
Samples were evaluated at a magnification of × 20 with




TEM allows a beam of coherent electrons to be directed
onto a sample under vacuum [58]. Owing to thescattering of electrons within the sample, small objects
inside the cell can be viewed directly [58]. This allows
for the study and subsequent better understanding of
biological structure-function relationships at cellular,
subcellular and molecular levels [58-60]. TEM was used
to provide precise intracellular information on the SNO
cells.
SNO cells were seeded in complete growth medium at
1.5 × 106 cells per 25 cm2 flask and were subsequently ex-
posed to ESE-16 and the appropriate controls. After the
24-hour incubation period, cells were trypsinized and the
samples were resuspended in 1 ml DMEM complete
medium. Samples were fixed with PBS:2.5% gluteralde-
hyde (9:1) solution for 45 min at room temperature and
then rinsed three times for 5 min each with PBS. Samples
were fixed again with osmium tetroxide for 15 min and
rinsed afterwards three times for 5 min each with PBS.
The samples were dehydrated with increasing ethanol
concentrations (30%, 50%, 70%, 90%, 100%) and left over-
night in 100% ethanol. Samples were then infiltrated and
embedded with 100% EMBED 812. Ultrathin sections
of the samples were prepared using a microtome and
were contrasted using 4% uranyl acetate for 5 min and
Reynolds’ lead citrate for 2 min, then rinsed with water
and viewed at a scale bar of between 2-10 μm with a
Multi-purpose Philips 301 TEM (Electron Microscopy
Unit, University of Pretoria, South Africa).
Confocal microscopy
Confocal-alpha (α)-tubulin assay
A confocal microscope creates sharp images by perform-
ing point-by-point image construction by focusing a
point of light sequentially across a specimen, excluding
most of the light from the specimen that is not from the
microscope’s focal plane [61]. Confocal microscopy was
employed to observe the effects of ESE-16 on the micro-
tubule tubulin dynamics of SNO cells after 24 hours’
exposure time.
SNO cells were seeded in complete growth medium at
5 × 105 cells in 6-well plates on heat-sterilized coverslips
and exposed to ESE-16 and the appropriate controls.
After the 24-hour incubation period the samples were
fixed with 1.5 ml glutaraldehyde fixer for 10 min at 37°C
and then permeabilized with 2 ml permeabilization buf-
fer for 15 min at room temperature. Samples were
stained first with a 100 μl mouse monoclonal antibody
against human α-tubulin (Clone 2-28-33; 1:1000) for
1.5 hours at 37°C. After the incubation period, samples
were washed with PBS for 5 min at room temperature
and then stained with a secondary antibody (biotin-con-
jugated anti-mouse IgG 58) in FITC-conjugate diluent
(100 μl), for 1.5 hours at 37°C. After three 5 min washes
with PBS, coverslips were stained with DAPI (2 ml), a
nucleic stain that produces blue fluorescence for 10 min
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glycerol-based mounting fluid on glass slides and viewed
with a Zeiss LSM 510 META confocal laser microscope
at the Electron Microscopy Unit at the University of
Pretoria (Pretoria, South Africa). Images taken by the
microscope were visualized at 10 μm with the use of




One of the earliest indications of apoptosis is the trans-
location of PS from the inner- to the outer leaflet of the
plasma membrane where it becomes exposed [8,62].
Annexin V is a Ca2+-dependent phospholipid binding
protein with a high affinity for PS [35,53,59] and is used
when conjugated to a fluorochrome (FITC) as an indica-
tor of early apoptosis [8,62].
SNO cells were seeded in complete growth medium at
1x106 cells per 25 cm2 flasks and were exposed to ESE-
16 and the appropriate controls. Samples were trypsi-
nized, resuspended in 1 ml 1x Binding Buffer and centri-
fuged at 300 × g for 10 min. Supernatant was removed
and samples were resuspended in 100 μl of the 1x Bind-
ing Buffer. Subsequently, 10 μl of Annexin V-FITC was
added and samples were incubated for 15 min in the
dark at room temperature. After incubation, samples
were washed with 1 ml 1x Binding Buffer and centri-
fuged at 300 × g for 10 min. Supernatant was carefully
pipetted off and samples were resuspended in 500 μl
1x Binding Buffer solution. The FL1 channel was used
to measure Annexin V-FITC fluorescence and was
conducted with an fluorescence-activated cell sorting
(FACS) FC500 system flow cytometer (Beckman Coulter
South Africa (Pty) Ltd) equipped with an air-cooled
argon laser with an excitation wavelength of 488 nm.
Mitochondrial membrane potential
The Mitotracker kit allows us to measure the ΔΨm by
labelling the mitochondria with a cationic dye named
“5,5′,6,6’-tetrachloro-1,133’-tetra-ethylbenzimidazolyl-
carbocyanine iodide”, which passively diffuses across the
plasma membrane and accumulate in active mitochon-
dria providing red fluorescence [36]. However, if there is
a reduction in ΔΨm, the dye cannot aggregate in the
mitochondria and thus remains in the cytoplasm in its
monomer form, generating green fluorescence [36].
SNO cells were seeded at 1 × 106 cells per 25 cm2 flask
and exposed to ESE-16 and the appropriate controls. Sam-
ples were trypsinized and centrifuged at 13 000 × g and
the supernatant was removed. Samples were resuspended
in 1 ml diluted Mitocapture solution and incubated at
37°C for 20 min. Samples were centrifuged at 500 × g, the
supernatant was removed and was resuspended in 1 mlpre-warmed (37°C) incubation buffer. Samples were ana-
lysed using an FACS FC500 System flow cytometer
equipped with an air-cooled argon laser excited at 488 nm
(Beckman Coulter South Africa (Pty) Ltd). Apoptotic cells
were detected in the FL1 FITC channel showing diffused
green fluorescence. Healthy cells were detected in the FL2
channel showing red fluorescence.Reactive oxygen species
In the mitochondria, ROS is generated via the electron
transport chain and can accumulate as by-products,
which can lead to mitochondrial proteins and mitochon-
drial DNA, causing loss of electron transport, decrease
in ATP production and ΔΨm dissipation [37-40]. In
addition, ROS accumulation is believed to act as signal-
ing molecules which initiates MMP, causing the release
of pro-apoptotic proteins [39,51]. Suspected O2
− gener-
ation was assessed using HE, an O2
− -sensitive dye that
is oxidized by O2
− to a red fluorescing compound [21,39].
SNO cells were seeded in complete growth medium at
1 × 106 cells per 25 cm2 flask and exposed to ESE-16
and the appropriate controls. Cells were trypsinized and
resuspended in 1 ml PBS. Samples were resuspended in
10 μM HE for 15 min at 37°C. Fluorescence was mea-
sured on the FL2 channel of an FACS FC500 System
flow cytometer (Beckman Coulter South Africa (Pty) Ltd
equipped with an air-cooled argon laser with an excita-
tion wavelength of 488 nm.Spectrophotometry
Caspase activity
The activity of caspase 9 and −3 as a result of ESE-16-
exposure was investigated with the use of a Caspase 9
and −3 Colorimetric Kit. The assays were based on the
detection of the chromophore p-nitroanilide (pNA) at a
wavelength of 405 nm via spectrophotometry.
SNO cells were seeded in complete growth medium at
1 × 106 cells per 25 cm2 flask and exposed to ESE-16 and
the appropriate controls. Cells were trypsinized and cen-
trifuged at 250 × g for 10 min. Supernatant was removed
and samples were lysed with the addition of cold lysis buf-
fer and were incubated on ice for 10 min. Samples were
centrifuged at 10 000 × g for 1 min and supernatant was
transferred to new tubes and kept on ice. This was ex-
pected to yield a cell lysate with an approximate protein
concentration of 2–4 mg/ml. Cell lysate (50 μl) were
added to wells in a 96-well plate. 2× Reaction Buffer
(50 μl) containing dithiothreitol (DDT) stock was added
to samples along with 5 μl of caspase-3/-9 colorimetric
substrate. The plate was incubated at 37°C for 1–2 hours.
Absorbance was determined at a wavelength of 405 nm
with the use of an ELx800 Universal Microplate Reader
(Bio-Tek Instruments Inc. Vermont, USA).
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Qualitative analysis was obtained via light microscopy,
confocal microscopy and TEM. Quantitative analysis
was obtained via mitotic indices, flow cytometry and
spectrophotometry. All experiments conducted were re-
peated three times. For the techniques that involved flow
cytometry, 10 000 to 30 000 events were counted for
each repeat and analysis of the data was done with the
use of the Cyflogic program, version 1.2.1, created by
Perttu Terho and Mika Korkeamäki from CyFlo Ltd.
based in Finland. Quantitative data were analysed for
significance by using student t-test statistics. A P-value
of <0.05 was regarded as statistically significant.Abbreviations
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